Metsera Inc (MTSR)

$29.57 -1.30 (-4.21%)
Market Cap 3.24B
Revenue (ttm) 0.00
Net Income (ttm) -209.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 644,501
Avg Vol 1,151,714
Day's Range N/A - N/A
Shares Out 105.06M
Stochastic %K 27%
Beta N/A
Analysts Strong Sell
Price Target $57.33

Company Profile

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, N...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 784 6595
Website: metsera.com
Address:
3 World Trade Center, 175 Greenwich Street, New York, United States
biolover
biolover Aug. 11 at 2:16 PM
$VKTX we have 2 M volume vs 80 K for $MTSR for anyone who forgot mechanisms reign in and was impressed by some biofunds movement.::
0 · Reply
himsssss
himsssss Aug. 9 at 4:41 AM
$VKTX $MTSR Lets be clear about this. Metsera had a massive run 100% gain and gains were taken. VKTX is now waking up after 4 months of that post, it finally shifted. You tell me? Where were you this whole time when Mesera gained to $48? I like how you try to take the screenshot out of context to make it look like you would lose money, but gains are clear here and youre still bagholding from the 60s.
1 · Reply
NoBagHoldingENT
NoBagHoldingENT Aug. 8 at 7:32 PM
$VKTX $MTSR $ALT is the cult still going to be mad at me or are they going to buy in and earn gains? Not too late. Data hasn't dropped yet.
2 · Reply
biolover
biolover Aug. 8 at 2:48 PM
$VKTX $LLY data unwinded everything that is based on single GLP1 R agonism. This is what you see with $MTSR and $GPCR stock performance. $AMGN Maritide is not more than single GLP1 agonist in efficacy with added vomiting experience due to GIP antagonism ( something we have been talking about for 2 years )
2 · Reply
Bayes_Theorem
Bayes_Theorem Aug. 8 at 2:36 PM
$MTSR $VKTX wya @himsssss
1 · Reply
Ohzipit
Ohzipit Aug. 7 at 9:00 PM
$GPCR $MTSR $PFE $VKTX Right Again!
0 · Reply
biolover
biolover Aug. 7 at 6:47 PM
$PFE $VKTX Look at $GPCR and $MTSR performance for all doubters.
1 · Reply
judgeyoung2
judgeyoung2 Aug. 7 at 5:05 PM
$LLY $MTSR $NVO $VKTX okay well we got a new NVO ceo and LLY data. next is VKTX data most likely and then MTSR data in September.
1 · Reply
Bropofol23
Bropofol23 Aug. 7 at 12:14 PM
$MTSR let’s go! Up pre market. Any news?
0 · Reply
smartkarma
smartkarma Aug. 7 at 10:34 AM
$MTSR | Metsera Inc (MTSR) Six Month Summary: The Bright Spot in a Quiet Biotech Year "​Metsera's stock offering priced above range, shares rally to $47.40, trajectory hinges on upcoming clinical trial data for MET-233i." - IPO Boutique (IPO Boutique) Read more: https://www.smartkarma.com/insights/metsera-inc-mtsr-six-month-summary-the-bright-spot-in-a-quiet-biotech-year
0 · Reply
Latest News on MTSR
Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

Jul 28, 2025, 4:01 PM EDT - 16 days ago

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 7:00 AM EDT - 2 months ago

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Jun 9, 2025, 2:07 PM EDT - 2 months ago

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Jun 9, 2025, 12:04 PM EDT - 2 months ago

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Jun 9, 2025, 7:00 AM EDT - 2 months ago

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Jun 5, 2025, 7:30 AM EDT - 2 months ago

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

May 12, 2025, 7:00 AM EDT - 3 months ago

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

Metsera to Present at Bank of America 2025 Global Healthcare Conference

May 8, 2025, 4:01 PM EDT - 3 months ago

Metsera to Present at Bank of America 2025 Global Healthcare Conference

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Mar 26, 2025, 7:00 AM EDT - 5 months ago

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

Feb 26, 2025, 7:00 AM EST - 6 months ago

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Feb 26, 2025, 3:55 AM EST - 6 months ago

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Why this newly public biotech could become a force in obesity treatments

Feb 25, 2025, 1:42 PM EST - 6 months ago

Why this newly public biotech could become a force in obesity treatments

This weight-loss drug stock could deliver a 90% return in 2025

Feb 25, 2025, 8:47 AM EST - 6 months ago

This weight-loss drug stock could deliver a 90% return in 2025

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

Feb 5, 2025, 4:01 PM EST - 6 months ago

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Feb 1, 2025, 2:10 AM EST - 6 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MAZE ODTX ODYS SAIL

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Jan 31, 2025, 12:42 PM EST - 6 months ago

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Weight-loss drug developer Metsera raises $275 million in US IPO

Jan 30, 2025, 7:05 PM EST - 6 months ago

Weight-loss drug developer Metsera raises $275 million in US IPO

Metsera Announces Pricing of Initial Public Offering

Jan 30, 2025, 6:53 PM EST - 6 months ago

Metsera Announces Pricing of Initial Public Offering

Metsera Readies $275 Million IPO For Obesity Treatments

Jan 28, 2025, 4:48 PM EST - 7 months ago

Metsera Readies $275 Million IPO For Obesity Treatments

Weight-loss drug developer Metsera reveals wider loss in US IPO filing

Jan 10, 2025, 6:02 PM EST - 7 months ago

Weight-loss drug developer Metsera reveals wider loss in US IPO filing

Metsera IPO Registration Document (S-1)

Jan 10, 2025, 4:46 PM EST - 7 months ago

Metsera IPO Registration Document (S-1)

biolover
biolover Aug. 11 at 2:16 PM
$VKTX we have 2 M volume vs 80 K for $MTSR for anyone who forgot mechanisms reign in and was impressed by some biofunds movement.::
0 · Reply
himsssss
himsssss Aug. 9 at 4:41 AM
$VKTX $MTSR Lets be clear about this. Metsera had a massive run 100% gain and gains were taken. VKTX is now waking up after 4 months of that post, it finally shifted. You tell me? Where were you this whole time when Mesera gained to $48? I like how you try to take the screenshot out of context to make it look like you would lose money, but gains are clear here and youre still bagholding from the 60s.
1 · Reply
NoBagHoldingENT
NoBagHoldingENT Aug. 8 at 7:32 PM
$VKTX $MTSR $ALT is the cult still going to be mad at me or are they going to buy in and earn gains? Not too late. Data hasn't dropped yet.
2 · Reply
biolover
biolover Aug. 8 at 2:48 PM
$VKTX $LLY data unwinded everything that is based on single GLP1 R agonism. This is what you see with $MTSR and $GPCR stock performance. $AMGN Maritide is not more than single GLP1 agonist in efficacy with added vomiting experience due to GIP antagonism ( something we have been talking about for 2 years )
2 · Reply
Bayes_Theorem
Bayes_Theorem Aug. 8 at 2:36 PM
$MTSR $VKTX wya @himsssss
1 · Reply
Ohzipit
Ohzipit Aug. 7 at 9:00 PM
$GPCR $MTSR $PFE $VKTX Right Again!
0 · Reply
biolover
biolover Aug. 7 at 6:47 PM
$PFE $VKTX Look at $GPCR and $MTSR performance for all doubters.
1 · Reply
judgeyoung2
judgeyoung2 Aug. 7 at 5:05 PM
$LLY $MTSR $NVO $VKTX okay well we got a new NVO ceo and LLY data. next is VKTX data most likely and then MTSR data in September.
1 · Reply
Bropofol23
Bropofol23 Aug. 7 at 12:14 PM
$MTSR let’s go! Up pre market. Any news?
0 · Reply
smartkarma
smartkarma Aug. 7 at 10:34 AM
$MTSR | Metsera Inc (MTSR) Six Month Summary: The Bright Spot in a Quiet Biotech Year "​Metsera's stock offering priced above range, shares rally to $47.40, trajectory hinges on upcoming clinical trial data for MET-233i." - IPO Boutique (IPO Boutique) Read more: https://www.smartkarma.com/insights/metsera-inc-mtsr-six-month-summary-the-bright-spot-in-a-quiet-biotech-year
0 · Reply
premarketmaker
premarketmaker Aug. 6 at 6:11 PM
$ETHE $GAME $MTSR $BTC
0 · Reply
premarketmaker
premarketmaker Aug. 6 at 6:05 PM
$ETHE - new highs - $GAME - has one of the highest Ethereum treasuries on record. GAMESQUARE HOLDINGS is the $MTSR of $BTC.
0 · Reply
GASKY
GASKY Aug. 5 at 9:57 PM
$MTSR Interesting..
0 · Reply
Theflash88
Theflash88 Aug. 4 at 7:17 PM
$MTSR My take. Near top of the list of buyout companies by big pharma.. $VKTX $ALT $MSTR $GPCR
0 · Reply
Doozio
Doozio Aug. 2 at 7:22 PM
$MSTR $MTSR 🐑👀
0 · Reply
finviz
finviz Jul. 31 at 1:06 AM
20 stocks that are short sale restricted and have a quick ratio over 2 include $QS $MTSR $NVTS and $OUST
1 · Reply
QuantInsider
QuantInsider Jul. 30 at 8:20 PM
$MTSR is heating up Big move with 409 ITM Aug 15 $30 call sweeps for a massive $393,590 premium at the ask That's some serious bullish conviction heading into mid-August Check this out 252-contract Aug 15 $30 call sweep paid $9.70 at the ask That’s $244,440 in premium with no puts to offset Traders clearly expecting more upside by expiration Momentum is strong Call buying is 2.4 times the norm and not a single put in sight This skewed bullish action could lift implied volatility and push MTSR higher over the next couple of weeks Keep an eye on it
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 30 at 2:43 PM
$MTSR Excellent article that nails exactly where MTSR stands right now. So if you want to update your MTSR knowledge or get acquainted with MTSR, this is a must read. https://beyondspx.com/article/metsera-unlocking-next-gen-obesity-treatment-with-differentiated-peptides-nasdaq-mtsr
0 · Reply
biolover
biolover Jul. 28 at 9:20 PM
$VKTX $MTSR is screwed up due to non titration with Vesper 1. I tried to advice them if they listen on X Read my expectations on X. As space allows long paragraphs https://x.com/bioinvestor24/status/1949942606055817679?s=46
3 · Reply
judgeyoung2
judgeyoung2 Jul. 28 at 8:13 PM
$MTSR Update: “MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025.”
0 · Reply
judgeyoung2
judgeyoung2 Jul. 28 at 1:06 PM
$MTSR $GRI $LLY one of you please give me data this week. thank you
0 · Reply
judgeyoung2
judgeyoung2 Jul. 23 at 4:23 PM
$MTSR release the data soon please
0 · Reply